IP Library › Granted Patent US 12,551,669
Granted Patent B2
US 12,551,669 · App. 17/376,554 · Granted Feb 17, 2026

Medical system including two access ports

Inventors: Daniel J. Abrams (Denver, CO); Lisa Lynn Shafer (Stillwater, MN); Dwight Skinner (New Brighton, MN)
Assignee: Biogen MA Inc.
A61M27/006A61M5/14276A61M5/158A61M5/165A61M39/0208A61M39/0247A61B2010/0077A61M5/1408A61M2005/14284A61M2025/0037A61M2039/025A61M2039/0264A61M2210/0687A61M2210/0693
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,551,669
App. No.
17/376,554
Granted
Feb 17, 2026
Kind
B2
Abstract

A system includes a first port comprising a first inlet, a first outlet, a first fluid pathway extending from the first inlet to the first outlet, a second inlet, a second outlet, and a second fluid pathway extending from the second inlet to the second outlet. The system further includes one or more CSF catheters having a first lumen, a first distal opening in fluid communication with the first lumen, a second lumen, and a second distal opening in fluid communication with the second lumen. The one or more CSF catheters are, or are configured to be, operatively coupled with the first implantable device such that the first lumen is in fluid communication with the first fluid pathway and the second lumen is in fluid communication with the second fluid pathway. At least the first distal opening is configured to be placed in the CSF-containing space. The system further includes a second port having a third inlet, a third outlet, and a third fluid pathway extending from the third inlet to the third outlet. The system also includes a port catheter configured to operatively couple the third fluid pathway to the second fluid pathway.

Claims (31)

1 . A system for infusing fluid into a CSF-containing space and for withdrawing fluid from the CSF-containing space, the system comprising:

a first port comprising a first inlet, a first outlet, a first fluid pathway extending from the first inlet to the first outlet, a second inlet, a second outlet, and a second fluid pathway extending from the second inlet to the second outlet;

one or more CSF catheters comprising a CSF catheter body, a first lumen, a first plurality of distal openings in fluid communication with the first lumen, a second lumen, and a second plurality of distal openings in fluid communication with the second lumen, wherein the one or more CSF catheters are, or are configured to be, operatively coupled with the first port such that the first lumen is in fluid communication with the first fluid pathway and the second lumen is in fluid communication with the second fluid pathway, wherein the first plurality of distal openings comprises a distal end opening disposed at a distal tip of the CSF catheter body and a plurality of first side openings, and

wherein at least the first plurality of distal openings are configured to be placed in the CSF-containing space;

a second port comprising a third inlet, a third outlet, and a third fluid pathway extending from the third inlet to the third outlet;

a port catheter connecting the third outlet to the second inlet and configured to operatively couple the third fluid pathway to the second fluid pathway; and

a port catheter connector extending parallel with a bottom surface of an upper flange portion of the first port and configured to couple the port catheter to the second inlet.

2 . The system of claim 1 , wherein the first inlet is configured to receive a needle to aspirate CSF fluid from the CSF-containing space.

3 . The system of claim 1 , wherein the first port is configured to be implanted in proximity to a skull.

4 . The system of claim 3 , wherein at least a portion of the first port is configured to be implanted in a burr hole in the skull.

5 . The system of claim 1 , wherein the third inlet is configured to receive a needle to introduce fluid through the third fluid pathway.

6 . The system of claim 1 , wherein the second port is implantable.

7 . The system of claim 6 , wherein the second port is configured to be implanted subcutaneously in second location on skull in proximity to an ear or in implanted subcutaneously in proximity to a clavicle.

8 . The system of claim 1 , wherein second port comprises a fourth inlet and a fourth fluid flow pathway extending from the fourth inlet to the third outlet.

9 . The system of claim 8 , further comprising an implantable infusion device and an infusion device catheter, wherein the infusion device catheter is configured to operatively couple the infusion device to the fourth inlet of the second port.

10 . The system of claim 1 , further comprising an infusion device and an infusion catheter, wherein the infusion catheter is configured to operatively couple the infusion device to the second fluid flow pathway of the first port.

11 . The system of claim 1 , wherein a first distance separates the plurality of first side openings and the distal tip.

12 . The system of claim 11 , wherein the second plurality of distal openings comprises: a plurality of second side openings, wherein a second distance separates the plurality of second side openings and the distal tip, wherein the second distance is greater than the first distance.

13 . The system of claim 1 , wherein a first lumen body portion and a second lumen body portion of the CSF catheter body are both configured to extend to the distal tip.

14 . The system of claim 1 , further comprising a second port catheter connector configured to couple the port catheter to the third outlet.

15 . The system of claim 1 , wherein the port catheter connector comprises a sleeve configured to receive the port catheter and a barbed fitting configured to be inserted into a lumen of the port catheter.

16 . A method comprising:

providing the system of claim 1 associated with a subject;

introducing a first therapeutic fluid into the third inlet of the second port to cause the therapeutic fluid to flow through the third pathway of the second port, through a lumen of the port catheter, through the second fluid pathway of the first port, through the second lumen of the CSF catheter, through the second plurality of distal openings of the CSF catheter in fluid communication with the second lumen of the CSF catheter, and into the subject; and

withdrawing CSF from the CSF-containing space of the subject through the first plurality of distal openings of the CSF catheter in fluid communication with the first lumen of the CSF catheter, through the first lumen of the CSF catheter, through the first passageway of the first port, and out of the first inlet of the first port.

17 . The method of claim 16 , wherein the first therapeutic fluid is introduced into the CSF-containing space.

18 . The method of claim 16 , wherein the system comprises an infusion device and an infusion catheter operatively coupled to the infusion device, and wherein the method further comprises introducing a second therapeutic fluid from the infusion device to the subject through the second plurality of distal openings of the CSF catheter in communication with the second lumen of the CSF catheter, wherein the first and second therapeutic fluids are the same or different.

19 . The method of claim 18 , wherein the first and second therapeutic fluids are the same.

20 . The method of claim 18 , further comprising uncoupling the port catheter from the third inlet of the second port and operatively coupling the infusion device catheter to the port catheter.

21 . The method of claim 18 , wherein the second port comprises the fourth inlet and the fourth fluid pathway extending from the fourth inlet to the third outlet, and wherein the infusion device catheter is operatively coupled to the fourth inlet.

22 . The method of claim 18 , wherein the second port and the infusion device are both operatively coupled to the port catheter.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2024
From: CEREBRAL THERAPEUTICS, INC.
To: BIOGEN MA INC.
Reel/Frame 069104/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2022
From: ABRAMS, DANIEL J.; SHAFER, LISA LYNN; SKINNER, DWIGHT
To: CEREBRAL THERAPEUTICS, INC.
Reel/Frame 060093/0528 →
Continuity (3)
Provisional Application 63209835 · Jun 11, 2021
Provisional Application 63052284 · Jul 15, 2020
Related Publication 20220016402A1 · Jan 20, 2022
References Cited (400)
US 1456469A · Schwidetzky · 1923 [cited by applicant]
US 2609818A · Parrine · 1952 [cited by applicant]
US 3040743A · Knut · 1962 [cited by applicant]
US 3506006A · Lange, Jr. · 1970 [cited by applicant]
US 3563373A · Paulson · 1971 [cited by applicant]
US 3640269A · Delgado · 1972 [cited by applicant]
US 3892237A · Steiner · 1975 [cited by applicant]
US 4281666A · Cosman · 1981 [cited by applicant]
US 4281667A · Cosman · 1981 [cited by applicant]
US 4464168A · Redmond et al. · 1984 [cited by applicant]
US 4500311A · Redmond et al. · 1985 [cited by applicant]
US 4583968A · Mahurkar · 1986 [cited by applicant]
US 4677985A · Bro et al. · 1987 [cited by applicant]
US 4723556A · Sussman · 1988 [cited by applicant]
US 4732850A · Brown et al. · 1988 [cited by applicant]
US 4767410A · Moden et al. · 1988 [cited by applicant]
US 4779763A · Klawitter · 1988 [cited by applicant]
US 4861335A · Reynolds · 1989 [cited by applicant]
US 4883101A · Strong · 1989 [cited by applicant]
US 4904241A · Bark · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 4958622A · Selenke · 1990 [cited by applicant]
US 5067948A · Haber et al. · 1991 [cited by applicant]
US 5197951A · Mahurkar · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5334163A · Sinnett · 1994 [cited by applicant]
US 5377864A · Blechl et al. · 1995 [cited by applicant]
US 5522807A · Luther · 1996 [cited by applicant]
US 5648237A · Carter · 1997 [cited by applicant]
US 5704352A · Tremblay et al. · 1998 [cited by applicant]
US 5720720A · Laske et al. · 1998 [cited by applicant]
US 5736137A · Anderson et al. · 1998 [cited by applicant]
US 5810789A · Powers et al. · 1998 [cited by applicant]
US 5823961A · Fields et al. · 1998 [cited by applicant]
US 5897528A · Schultz · 1999 [cited by applicant]
US 5902331A · Bonner et al. · 1999 [cited by applicant]
US 6001806A · Hilbert et al. · 1999 [cited by applicant]
US 6006124A · Fischell et al. · 1999 [cited by applicant]
US 6013051A · Nelson · 2000 [cited by applicant]
US 6018036A · Mosmann et al. · 2000 [cited by applicant]
US 6086555A · Eliasen et al. · 2000 [cited by applicant]
US 6113578A · Brown · 2000 [cited by applicant]
US 6248080B1 · Miesel et al. · 2001 [cited by applicant]
US 6248126B1 · Lesser et al. · 2001 [cited by applicant]
US 6293922B1 · Haase · 2001 [cited by applicant]
US 6324433B1 · Errico · 2001 [cited by applicant]
US 6451977B1 · De Sauvage et al. · 2002 [cited by applicant]
US 6458943B1 · Byrne · 2002 [cited by applicant]
US 6475987B1 · Shu · 2002 [cited by applicant]
US 6482185B1 · Hartmann · 2002 [cited by applicant]
US 6562023B1 · Marrs et al. · 2003 [cited by applicant]
US 6573099B2 · Graham · 2003 [cited by applicant]
US 6595979B1 · Epstein et al. · 2003 [cited by applicant]
US 6632927B2 · Adair et al. · 2003 [cited by applicant]
US 6720138B2 · Sharma et al. · 2004 [cited by applicant]
US 6753139B1 · Baulcombe et al. · 2004 [cited by applicant]
US 7056704B2 · Tuschl et al. · 2006 [cited by applicant]
US 7083785B2 · Browning et al. · 2006 [cited by applicant]
US 7112421B2 · Ambrose et al. · 2006 [cited by applicant]
US 7161488B2 · Frasch · 2007 [cited by applicant]
US 7195616B2 · Diller et al. · 2007 [cited by applicant]
US 7359765B2 · Varvarelis et al. · 2008 [cited by applicant]
US 7371388B1 · Ruben et al. · 2008 [cited by applicant]
US 7618409B2 · Hochman · 2009 [cited by applicant]
US 7670327B2 · Kucharczyk et al. · 2010 [cited by applicant]
US 7883502B2 · Powers et al. · 2011 [cited by applicant]
US 7917222B1 · Osorio et al. · 2011 [cited by applicant]
US 7922695B2 · Wiegel et al. · 2011 [cited by applicant]
US 8066681B1 · Hall et al. · 2011 [cited by applicant]
US 8277425B2 · Girard et al. · 2012 [cited by applicant]
US 8409133B2 · Pesach et al. · 2013 [cited by applicant]
US 8556866B2 · Krulevitch et al. · 2013 [cited by applicant]
US 8744544B2 · Najafi et al. · 2014 [cited by applicant]
US 8808234B2 · Vogelbaum et al. · 2014 [cited by applicant]
US 8827964B2 · Boyd et al. · 2014 [cited by applicant]
US 8979822B2 · Vogelbaum et al. · 2015 [cited by applicant]
US 9913960B2 · Blanchard et al. · 2018 [cited by applicant]
US 10506988B2 · Karoly et al. · 2019 [cited by applicant]
US 10716921B2 · Purdy · 2020 [cited by applicant]
US 10967172B1 · Shire et al. · 2021 [cited by applicant]
US 11504516B2 · Otto · 2022 [cited by applicant]
US 11534592B2 · Singh et al. · 2022 [cited by applicant]
US 12097029B1 · Shanechi · 2024 [cited by applicant]
US 20020004643A1 · Carmel et al. · 2002 [cited by applicant]
US 20020052563A1 · Penn et al. · 2002 [cited by applicant]
US 20020086356A1 · Tuschl et al. · 2002 [cited by applicant]
US 20030012783A1 · Kindsvogel · 2003 [cited by applicant]
US 20030069623A1 · Stypulkowski · 2003 [cited by applicant]
US 20030097051A1 · Kolberg et al. · 2003 [cited by applicant]
US 20030108923A1 · Tuschl et al. · 2003 [cited by applicant]
US 20030135148A1 · Dextradeur et al. · 2003 [cited by applicant]
US 20030204075A9 · Wang · 2003 [cited by applicant]
US 20030216714A1 · Gill · 2003 [cited by examiner]
US 20030228691A1 · Lewis et al. · 2003 [cited by applicant]
US 20040002677A1 · Gentsler · 2004 [cited by applicant]
US 20040053411A1 · Cullen et al. · 2004 [cited by applicant]
US 20040069044A1 · Lavi et al. · 2004 [cited by applicant]
US 20040073196A1 · Adams et al. · 2004 [cited by applicant]
US 20040082984A1 · Osorio et al. · 2004 [cited by applicant]
US 20040086884A1 · Beach et al. · 2004 [cited by applicant]
US 20040102412A1 · Broschat et al. · 2004 [cited by applicant]
US 20040106566A1 · Lin et al. · 2004 [cited by applicant]
US 20040112411A1 · Boykin et al. · 2004 [cited by applicant]
US 20040152112A1 · Croce et al. · 2004 [cited by applicant]
US 20040171037A1 · Li et al. · 2004 [cited by applicant]
US 20040171983A1 · Sparks et al. · 2004 [cited by applicant]
US 20040175732A1 · Rana · 2004 [cited by applicant]
US 20040210951A1 · Baulcombe et al. · 2004 [cited by applicant]
US 20040215162A1 · Putz · 2004 [cited by applicant]
US 20040221337A1 · Baulcombe et al. · 2004 [cited by applicant]
US 20040229266A1 · Tuschl et al. · 2004 [cited by applicant]
US 20040253604A1 · Lin et al. · 2004 [cited by applicant]
US 20040259247A1 · Tuschl et al. · 2004 [cited by applicant]
US 20040259248A1 · Tuschl et al. · 2004 [cited by applicant]
US 20040268441A1 · Vance et al. · 2004 [cited by applicant]
US 20050004219A1 · Hildebrand et al. · 2005 [cited by applicant]
US 20050026278A1 · Tuschl et al. · 2005 [cited by applicant]
US 20050037988A1 · Zamore et al. · 2005 [cited by applicant]
US 20050038371A1 · Reich et al. · 2005 [cited by applicant]
US 20050059005A1 · Tuschl et al. · 2005 [cited by applicant]
US 20050059011A1 · Sin et al. · 2005 [cited by applicant]
US 20050070458A1 · John · 2005 [cited by applicant]
US 20050074788A1 · Dahlberg et al. · 2005 [cited by applicant]
US 20050075492A1 · Chen et al. · 2005 [cited by applicant]
US 20050079614A1 · Reinhart et al. · 2005 [cited by applicant]
US 20050137578A1 · Heruth et al. · 2005 [cited by applicant]
US 20050163775A1 · Chan et al. · 2005 [cited by applicant]
US 20050209332A1 · Kuppuswamy et al. · 2005 [cited by applicant]
US 20050228315A1 · Ayad · 2005 [cited by applicant]
US 20050245906A1 · Makower et al. · 2005 [cited by applicant]
US 20060004317A1 · Mauge et al. · 2006 [cited by applicant]
US 20060067933A1 · Gross et al. · 2006 [cited by applicant]
US 20060073146A1 · Ashkenazi et al. · 2006 [cited by applicant]
US 20060079834A1 · Tennican et al. · 2006 [cited by applicant]
US 20060084055A1 · Gaiger et al. · 2006 [cited by applicant]
US 20060122677A1 · Vardiman · 2006 [cited by applicant]
US 20060160889A1 · Veeneman et al. · 2006 [cited by applicant]
US 20060286093A1 · Gross et al. · 2006 [cited by applicant]
US 20070073228A1 · Mernoe et al. · 2007 [cited by applicant]
US 20070078438A1 · Okada · 2007 [cited by applicant]
US 20070083063A1 · Nelson et al. · 2007 [cited by applicant]
US 20070086979A1 · Chevrier et al. · 2007 [cited by applicant]
US 20070123758A1 · Miesel et al. · 2007 [cited by applicant]
US 20070185017A1 · Aggarwal et al. · 2007 [cited by applicant]
US 20070197957A1 · Hunter et al. · 2007 [cited by applicant]
US 20070255237A1 · Lobl et al. · 2007 [cited by applicant]
US 20070260375A1 · Hilton · 2007 [cited by applicant]
US 20080027346A1 · Litt et al. · 2008 [cited by applicant]
US 20080039774A1 · Zawacki et al. · 2008 [cited by applicant]
US 20080058476A1 · Whiteker et al. · 2008 [cited by applicant]
US 20080132980A1 · Gerber · 2008 [cited by applicant]
US 20080147006A1 · Brunnberg et al. · 2008 [cited by applicant]
US 20080262374A1 · Gerber et al. · 2008 [cited by applicant]
US 20090030480A1 · Durand et al. · 2009 [cited by applicant]
US 20090069267A1 · Abrams et al. · 2009 [cited by applicant]
US 20090069742A1 · Larsen · 2009 [cited by applicant]
US 20090112327A1 · Lane et al. · 2009 [cited by applicant]
US 20090131850A1 · Geiger · 2009 [cited by applicant]
US 20090131857A1 · Geiger · 2009 [cited by examiner]
US 20090137944A1 · Haarala et al. · 2009 [cited by applicant]
US 20090203983A1 · Carlton et al. · 2009 [cited by applicant]
US 20090228066A1 · Hirata et al. · 2009 [cited by applicant]
US 20100036477A1 · Bronson et al. · 2010 [cited by applicant]
US 20100089167A1 · Trieu et al. · 2010 [cited by applicant]
US 20100145162A1 · Devauchelle et al. · 2010 [cited by applicant]
US 20100145176A1 · Himes · 2010 [cited by applicant]
US 20100158869A1 · Kaemmerer · 2010 [cited by applicant]
US 20100168532A1 · Waziri et al. · 2010 [cited by applicant]
US 20100210958A1 · Manwaring et al. · 2010 [cited by applicant]
US 20100241088A1 · Ranalletta et al. · 2010 [cited by applicant]
US 20100280335A1 · Carlson et al. · 2010 [cited by applicant]
US 20100286585A1 · Dimauro et al. · 2010 [cited by applicant]
US 20100305492A1 · Lad et al. · 2010 [cited by applicant]
US 20110009821A1 · Jespersen et al. · 2011 [cited by applicant]
US 20110009933A1 · Barker · 2011 [cited by applicant]
US 20110033463A1 · Thakker et al. · 2011 [cited by applicant]
US 20110066072A1 · Kawoos et al. · 2011 [cited by applicant]
US 20110092921A1 · Beling et al. · 2011 [cited by applicant]
US 20110172633A1 · Ali et al. · 2011 [cited by applicant]
US 20110201944A1 · Higgins et al. · 2011 [cited by applicant]
US 20110257596A1 · Gaudet · 2011 [cited by applicant]
US 20110264033A1 · Jensen et al. · 2011 [cited by applicant]
US 20110270095A1 · Bukhman · 2011 [cited by applicant]
US 20110270230A1 · Sage et al. · 2011 [cited by applicant]
US 20110275930A1 · Jho et al. · 2011 [cited by applicant]
US 20120015336A1 · Mach · 2012 [cited by applicant]
US 20120087869A1 · Thakker et al. · 2012 [cited by applicant]
US 20120245529A1 · Hummen et al. · 2012 [cited by applicant]
US 20120290225A1 · Julian et al. · 2012 [cited by applicant]
US 20120296271A1 · Yomtov et al. · 2012 [cited by applicant]
US 20120296404A1 · Carpentier et al. · 2012 [cited by applicant]
US 20120302959A1 · Fielder et al. · 2012 [cited by applicant]
US 20120310140A1 · Kramer et al. · 2012 [cited by applicant]
US 20130204229A1 · Olson et al. · 2013 [cited by applicant]
US 20130253266A1 · Dextradeur et al. · 2013 [cited by applicant]
US 20130267928A1 · Imran et al. · 2013 [cited by applicant]
US 20130324945A1 · Sabin · 2013 [cited by applicant]
US 20140012209A1 · Sansoucy · 2014 [cited by applicant]
US 20140074060A1 · Imran · 2014 [cited by examiner]
US 20140081347A1 · Nelson et al. · 2014 [cited by applicant]
US 20140148780A1 · Putz · 2014 [cited by applicant]
US 20140194825A1 · Nielsen et al. · 2014 [cited by applicant]
US 20140207074A1 · Nielsen · 2014 [cited by applicant]
US 20140236259A1 · Colantonio · 2014 [cited by applicant]
US 20140249410A1 · Uber, III et al. · 2014 [cited by applicant]
US 20140257168A1 · Gill · 2014 [cited by applicant]
US 20140276416A1 · Nelson et al. · 2014 [cited by applicant]
US 20150038901A1 · Lampropoulos et al. · 2015 [cited by applicant]
US 20150202373A1 · Creaturo · 2015 [cited by applicant]
US 20150209505A1 · Hanson et al. · 2015 [cited by applicant]
US 20150230724A1 · Waziri et al. · 2015 [cited by applicant]
US 20150238685A1 · Elias et al. · 2015 [cited by applicant]
US 20150297874A1 · East et al. · 2015 [cited by applicant]
US 20150306302A1 · Marsden · 2015 [cited by examiner]
US 20150367067A1 · Minaie et al. · 2015 [cited by applicant]
US 20160122282A1 · Kandula · 2016 [cited by applicant]
US 20160213312A1 · Singh et al. · 2016 [cited by applicant]
US 20160374901A9 · Rodriguez et al. · 2016 [cited by applicant]
US 20170007621A1 · Wotton et al. · 2017 [cited by applicant]
US 20170173267A1 · Ashmead et al. · 2017 [cited by applicant]
US 20170325685A1 · Shachar · 2017 [cited by examiner]
US 20170365101A1 · Samec et al. · 2017 [cited by applicant]
US 20180028746A1 · Abrams et al. · 2018 [cited by applicant]
US 20180028824A1 · Pivonka et al. · 2018 [cited by applicant]
US 20180104459A1 · Anand · 2018 [cited by examiner]
US 20180107798A1 · Hu · 2018 [cited by applicant]
US 20180107998A1 · Pederson · 2018 [cited by applicant]
US 20180140810A1 · Cataltepe · 2018 [cited by applicant]
US 20180193562A1 · Gibson et al. · 2018 [cited by applicant]
US 20180263752A1 · Pinchuk et al. · 2018 [cited by applicant]
US 20190030322A1 · Schulte et al. · 2019 [cited by applicant]
US 20190082990A1 · Poltorak · 2019 [cited by applicant]
US 20190105019A1 · Pagoulatos et al. · 2019 [cited by applicant]
US 20190151239A1 · Abrams et al. · 2019 [cited by applicant]
US 20190167964A1 · Lewis et al. · 2019 [cited by applicant]
US 20190218334A1 · Delaney, Jr. et al. · 2019 [cited by applicant]
US 20190246989A1 · Genov et al. · 2019 [cited by applicant]
US 20190282802A1 · Malinowski · 2019 [cited by applicant]
US 20190321106A1 · Bergman et al. · 2019 [cited by applicant]
US 20190351209A1 · Butziger et al. · 2019 [cited by applicant]
US 20200061337A1 · Singh et al. · 2020 [cited by applicant]
US 20200069254A1 · Lange et al. · 2020 [cited by applicant]
US 20200086538A1 · Funaoka · 2020 [cited by applicant]
US 20200170542A1 · Waziri et al. · 2020 [cited by applicant]
US 20200338325A1 · Shachar et al. · 2020 [cited by applicant]
US 20200375492A1 · Govari · 2020 [cited by applicant]
US 20210077714A1 · Bodner · 2021 [cited by applicant]
US 20210100990A1 · Yoo et al. · 2021 [cited by applicant]
US 20210205623A1 · Peterson et al. · 2021 [cited by applicant]
US 20210252266A1 · Karl-Heinz · 2021 [cited by applicant]
US 20210260280A1 · Gordon et al. · 2021 [cited by applicant]
US 20210327029A1 · Chen et al. · 2021 [cited by applicant]
US 20210338992A1 · Bertrand · 2021 [cited by applicant]
US 20210386982A1 · Lad et al. · 2021 [cited by applicant]
US 20210397970A1 · Cherian et al. · 2021 [cited by applicant]
US 20220016338A1 · Abrams et al. · 2022 [cited by applicant]
US 20220016402A1 · Abrams et al. · 2022 [cited by applicant]
US 20220016404A1 · Abrams et al. · 2022 [cited by applicant]
US 20220022800A1 · Abrams et al. · 2022 [cited by applicant]
US 20220249190A1 · Kelly et al. · 2022 [cited by applicant]
US 20220331567A1 · Abrams · 2022 [cited by applicant]
US 20230148923A1 · Abrams et al. · 2023 [cited by applicant]
US 20230200707A1 · Abrams et al. · 2023 [cited by applicant]
US 20230277840A1 · Abrams et al. · 2023 [cited by applicant]
US 20240021313A1 · Alkaitis et al. · 2024 [cited by applicant]
CA 3098311A1 · 2019 [cited by applicant]
DE 3127882A1 · 1983 [cited by applicant]
DE 102013002763A1 · 2014 [cited by applicant]
EP 0904119 · 1999 [cited by applicant]
EP 1281758A2 · 2003 [cited by applicant]
EP 1391219A2 · 2004 [cited by applicant]
EP 1391219A3 · 2004 [cited by applicant]
EP 1798243A2 · 2007 [cited by applicant]
EP 3028727A1 · 2016 [cited by applicant]
EP 0995460 · 2022 [cited by applicant]
JP 2004533997A · 2004 [cited by applicant]
JP 2007309746A · 2007 [cited by applicant]
KR 102054445B1 · 2019 [cited by applicant]
WO 9406690A1 · 1994 [cited by applicant]
WO 9427587A2 · 1994 [cited by applicant]
WO 1996033761 · 1996 [cited by applicant]
WO 0040716A2 · 2000 [cited by applicant]
WO 0068378A1 · 2000 [cited by applicant]
WO 0160397A1 · 2001 [cited by applicant]
WO 0168836A2 · 2001 [cited by applicant]
WO 0175164A2 · 2001 [cited by applicant]
WO 0244321A2 · 2002 [cited by applicant]
WO 02066516A2 · 2002 [cited by applicant]
WO 02094185A2 · 2002 [cited by applicant]
WO 03013582A1 · 2003 [cited by applicant]
WO 03029459A2 · 2003 [cited by applicant]
WO 03062401A2 · 2003 [cited by applicant]
WO 03070884A2 · 2003 [cited by applicant]
WO 03070903A2 · 2003 [cited by applicant]
WO 03070918A2 · 2003 [cited by applicant]
WO 03072713A2 · 2003 [cited by applicant]
WO 03074566A2 · 2003 [cited by applicant]
WO 03074654A2 · 2003 [cited by applicant]
WO 2004009779A2 · 2004 [cited by applicant]
WO 2004031412A2 · 2004 [cited by applicant]
WO 2004039956A2 · 2004 [cited by applicant]
WO 2004057017A2 · 2004 [cited by applicant]
WO 2004066183A2 · 2004 [cited by applicant]
WO 2004072248A2 · 2004 [cited by applicant]
WO 2004111191A2 · 2004 [cited by applicant]
WO 2004112411A1 · 2004 [cited by applicant]
WO 2005000351A2 · 2005 [cited by applicant]
WO 2005012523A1 · 2005 [cited by applicant]
WO 2005017111A2 · 2005 [cited by applicant]
WO 2005019453A2 · 2005 [cited by applicant]
WO 2005023200A2 · 2005 [cited by applicant]
WO 2005023986A2 · 2005 [cited by applicant]
WO 2005033271A2 · 2005 [cited by applicant]
WO 2005035769A2 · 2005 [cited by applicant]
WO 2005041859A2 · 2005 [cited by applicant]
WO 2005042705A2 · 2005 [cited by applicant]
WO 2006068867A1 · 2006 [cited by applicant]
WO 2007019618A1 · 2007 [cited by applicant]
WO 2007070538A2 · 2007 [cited by applicant]
WO 2008112017A2 · 2008 [cited by applicant]
WO 2008115919A2 · 2008 [cited by applicant]
WO 2008141321 · 2008 [cited by applicant]
WO 2009014762A1 · 2009 [cited by applicant]
WO 2009024562A1 · 2009 [cited by applicant]
WO 2009151741A1 · 2009 [cited by applicant]
WO 2010056712A1 · 2010 [cited by applicant]
WO 2011097487A2 · 2011 [cited by applicant]
WO 2013004843A1 · 2013 [cited by applicant]
WO 2014064691A2 · 2014 [cited by applicant]
WO 2014159757A2 · 2014 [cited by applicant]
WO 2014188407A1 · 2014 [cited by applicant]
WO 2015001008A1 · 2015 [cited by applicant]
WO 2015197867A1 · 2015 [cited by applicant]
WO 2016140853A1 · 2016 [cited by applicant]
WO 2018023041 · 2018 [cited by applicant]
WO 2018038930A1 · 2018 [cited by applicant]
WO 2018153943A1 · 2018 [cited by applicant]
WO 2019084038A1 · 2019 [cited by applicant]
WO 2019136462A1 · 2019 [cited by applicant]
WO 2019211314A1 · 2019 [cited by applicant]
WO 2020160613A1 · 2020 [cited by applicant]
WO 2020248067A1 · 2020 [cited by applicant]
WO 2021150522A1 · 2021 [cited by applicant]
WO 2022015941A1 · 2022 [cited by applicant]
WO 2022020314A1 · 2022 [cited by applicant]
International Search Report and Written Opinion from PCT App. No. PCT/US2021/041766 dated Nov. 25, 2021, 14 pages. [cited by applicant]
Written Opinion from PCT App. No. PCT/US2021/041766 dated May 30, 2022, 7 pages. [cited by applicant]
Leontariti et al., “Circulating miR-146a and miR-134 in predicting drug-resistant epilepsy in patients with focal impaired awareness seizures” May 2020 Epilepsia, 61(5):959-970. [cited by applicant]
Lubrizol Corporation, webinar, “Materials for Implantable Devices: Decoding Thermoplastic Polyurethanes” copyright 2022. Available on the world wide web at: lubrizol.com/Health/Medical/Resource-Hub/Webinars/Materials-fo… [cited by applicant]
Caudy et al., “Fragile X-related protein and VIG associate with the RNA interference machinery.” Genes & development 16.19 (2002): 2491-2496. [cited by applicant]
Cawley et al., “Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs.” Cell 116.4 (2004): 499-509. [cited by applicant]
Cerutti H., “RNA interference: traveling in the cell and gaining functions.” Trends in Genetics 19.1 (2003): 39-46. [cited by applicant]
Chang et al., “MicroRNAs act sequentially and asymmetrically to control chemosensory laterality in the nematode.” Nature 430.7001 (2004): 785-789. [cited by applicant]
Chang et al., “miR-122, a mammalian liver-specific microRNA, is processed from hor mRNA and maydownregulate the high affinity cationic amino acid transporter CAT-1.” RNA biology 1.2 (2004): 106-113. [cited by applicant]
Chang et al., “Resistance of human hepatitis delta virus RNAs to dicer activity.” Journal of virology 77.22 (2003): 11910-11917. [cited by applicant]
Chang P., “Encapsulation for somatic gene therapy.” Annals of the New York Academy of Sciences 875.1 (1999): 146-158. [cited by applicant]
Chapman et al., “Viral RNA silencing suppressors inhibit the microRNA pathway at an intermediate step.” Genes & development 18.10 (2004): 1179-1186. [cited by applicant]
Chapoval et al., “Anti-CD3 x anti-tumor F (ab') 2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.” Journal of immunology 155.3 (1995): 1296-1303. [cited by applicant]
Chattopadhyay et al., “Lack of impact of the loss of constitutive folate receptor a expression, achieved by RNA interference, on the activity of the new generation antifolate pemetrexed in HeLa cells.” Clinical cancer r… [cited by applicant]
Chen et al., “A bioinformatics based approach to discover small RNA genes in the [cited by applicant]
Chen et al., “A simple framework for contrastive learning of visual representations.” International conference on machine learning (2020): 1-11. [cited by applicant]
Chen et al., “Automatic sleep stage classification based on subthalamic local field potentials.” IEEE Transactions on Neural Systems and Rehabilitation Engineering 27.2 (2019): 118-128. [cited by applicant]
Chen et al., “Improved baselines with momentum contrastive learning.” arXiv preprint arXiv:2003.04297 (2020): 1-3. [cited by applicant]
Chen et al., “MicC, a second small-RNA regulator of Omp protein expression in [cited by applicant]
Chen et al., “MicroRNAs as regulators of mammalian hematopoiesis.” Seminars in immunology 17 (2005): 155-165. [cited by applicant]
Chen et al., “MicroRNAs modulate hematopoietic lineage differentiation.” science 303.5654 (2004): 83-86. [cited by applicant]
Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.” Journal of molecular biology 293.4 (1999): 865-881. [cited by applicant]
Chen et al., “Viral virulence protein suppresses RNA silencing—mediated defense but upregulates the role of microRNA in host gene expression.” The Plant Cell 16.5 (2004): 1302-1313. [cited by applicant]
Chen T., “Advancing Self-Supervised and Semi-Supervised Learning with SimCLR,” Blog.research.google, Retrieved from the Internet: <URL: https://research.google/blog/advancing-self-supervised-and-semi-supervised-learning… [cited by applicant]
Chen X., “A microRNA as a translational repressor of APETALA2 in [cited by applicant]
Cheng et al., “Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis.” Nucleic acids research 33.4 (2005): 1290-1297. [cited by applicant]
Cheng et al., “Stem cells: from epigenetics to microRNAs.” Neuron 46.3 (2005): 363-367. [cited by applicant]
Chesnut et al., “The role of secondary brain injury in determining outcome from severe head injury.” Journal of Trauma and Acute Care Surgery 34.2 (1993): 216-222. [cited by applicant]
Chiu et al., “Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.” Blood 109.2 (2007): 729-739. [cited by applicant]
Cios K., “Deep Neural Networks—A Brief History.” in: Gaweda et al., Advances in Data Analysis with Computational Intelligence Methods, vol. 378 (2018): 183-200. [cited by applicant]
Clark et al., “How does B cell depletion therapy work, and how can it be improved.” Annals of the rheumatic diseases 64.suppl 4 (2005): iv77-iv80. [cited by applicant]
Clarke et al., “Computer-assisted EEG diagnostic review for idiopathic generalized epilepsy.” Epilepsy & Behavior 121 (2021): 1-18. [cited by applicant]
Cobb et al., “Tracing microRNA patterns in mice.” Nature genetics 36.10 (2004): 1033-1034. [cited by applicant]
Coburn et al., “Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference.” Journal of virology 76.18 (2002): 9225-9231. [cited by applicant]
Coenen et al., “What work-related exposures are associated with post-traumatic stress disorder? A systematic review with meta-analysis.” BMJ open 11.8 (2021): 1-12. [cited by applicant]
Cogoni et al., “Post-transcriptional gene silencing across kingdoms.” Current opinion in genetics & development 10.6 (2000): 638-643. [cited by applicant]
Cohen et al., “Neuronal overexpression of ‘readthrough’ acetylcholinesterase is associated with antisense-suppressible behavioral impairments.” Molecular psychiatry 7.8 (2002): 874-885. [cited by applicant]
Cohen J., “Statistical Power Analysis for the Behavioral Sciences.” (Cover page, title page, and table of contents), 2nd Edition (1988): 1-8. [cited by applicant]
Colciaghi et al., “Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease.” Neurology 62.3 (2004): 498-501. [cited by applicant]
Cole et al., “Direct labeling of RNA with multiple biotins allows sensitive expression profiling of acute leukemia class predictor genes.” Nucleic acids research 32.11 (2004): 1-9. [cited by applicant]
Collins et al., “Long subcutaneous tunnelling reduces infection rates in paediatric external ventricular drains.” Child's Nervous System 30.10 (2014): 1671-1678. [cited by applicant]
Colsky et al., “FcR-Independent Antibody-Mediated Cellular Cytotoxicity.” Journal of leukocyte biology 49.6 (1991): 548-555. [cited by applicant]
Conner et al., “Posttraumatic stress disorder and suicide in 5.9 million individuals receiving care in the veterans health administration health system.” Journal of affective Disorders 166 (2014): 1-5. [cited by applicant]
Connolly et al., “Characterization of the relationship between intracranial pressure and electroencephalographic monitoring in burst-suppressed patients.” Neurocritical care 22.2 (2015): 212-220. [cited by applicant]
Connor et al., “Fluoxetine in post-traumatic stress disorder: randomised, double-blind study.” The British Journal of Psychiatry 175.1 (1999): 17-22. [cited by applicant]
Conrad C., “Chronic stress-induced hippocampal vulnerability: the glucocorticoid vulnerability hypothesis.” Reviews in the Neurosciences 19.6 (2008): 395-412. [cited by applicant]
Conrad C., “What is the functional significance of chronic stress-induced CA3 dendritic retraction within the hippocampus.” Behavioral and cognitive neuroscience reviews 5.1 (2006): 41-60. [cited by applicant]
Conway et al., “Chronic vagus nerve stimulation significantly improves quality of life in treatment-resistant major depression.” The Journal of Clinical Psychiatry 79.5 (2018): 52-59. [cited by applicant]
Cook et al., “Anti-seizure therapy with a long-term, implanted intra-cerebroventricular delivery system for drug-resistant epilepsy: A first-in-man study.” EClinicalMedicine 22 (2020): 1-9. [cited by applicant]
Cook et al., “Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study.” The Lancet Neurology 12.6 (2013): 563-571. [cited by applicant]
Coquery et al., “Regulatory roles of the tumor necrosis factor receptor BCMA.” Critical Review in Immunology 32.4 (2012): 287-305. [cited by applicant]
Coquery et al., “T follicular helper cells contribute to autoimmunity through the BCMA-BAFF axis (BA2P. 117).” The Journal of Immunology 192.Supplement_1 (2014): 45-4. [cited by applicant]
Courtney et al., “Links between traumatic brain injury and ballistic pressure waves originating in the thoracic cavity and extremities.” Brain Injury 21.7 (2007): 657-662. [cited by applicant]
Courtois et al., “Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults.” adopted as APA Policy on Feb. 24, 2017, American Psychological Association, 139 pages. [cited by applicant]
Gaudilliere et al., “RNA interference reveals a requirement for myocyte enhancer factor 2A in activity-dependent neuronal survival.” Journal of Biological Chemistry 277.48 (2002): 46442-46446. [cited by applicant]